Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Novartis (SWX:NOVN) reported final two year Phase III results for Fabhalta in IgA nephropathy.
Data showed significant long term kidney function improvement and a strong safety profile.
Results were published in the New England Journal of Medicine and shared at a major nephrology congress.
For investors, this update highlights how SWX:NOVN is focusing on specialty kidney care alongside its broader pharmaceutical portfolio. IgA nephropathy is a progressive and debilitating kidney disease with limited treatment options, so a potential new standard of care can be important for both patients and the company’s positioning in nephrology. Priority review status for Fabhalta also keeps regulatory timing in focus for the market.
This Phase III readout and high profile publication give investors additional detail on how Fabhalta could fit into treatment pathways if approved. Attention now turns to how regulators assess the data and how nephrologists ultimately view Fabhalta’s risk benefit profile compared with existing options.
Stay updated on the most important news stories for Novartis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novartis.
SWX:NOVN Earnings & Revenue Growth as at Apr 2026
We’ve flagged 1 risk for Novartis. See which could impact your investment.
⚖️ Price vs Analyst Target: At CHF123.20 versus an average analyst target of about CHF123.39, the share price is almost exactly in line with consensus.
✅ Simply Wall St Valuation: Simply Wall St currently views the shares as undervalued, with the stock trading about 58% below its estimated fair value.
❌ Recent Momentum: The 30 day return is essentially flat at around 0.05% decline, suggesting the market has not rerated the stock on this news yet.
To decide whether to buy, sell or hold Novartis, you can review the latest analysis of Novartis’s fair value on Simply Wall St. Head to the company report for the latest analysis of Novartis’s Fair Value..
📊 The Fabhalta Phase III data in IgA nephropathy highlights Novartis’s focus on specialty kidney care, which can influence how you view its long term product mix.
📊 Watch regulatory milestones following the priority review, prescriptions uptake assumptions, and how Fabhalta could support Novartis’s CHF56,674m revenue base over time.
⚠️ Simply Wall St flags one minor risk linked to debt levels, so it is worth checking how future pipeline spending and acquisitions might affect the balance sheet.
For the full picture including more risks and rewards, check out the complete Novartis analysis. Alternatively, you can visit the community page for Novartis to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com